FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

MGF

Mechano Growth Factor / IGF-1Ec

Growth Factors

Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (specifically the IGF-1Ec isoform in humans) that is expressed locally in muscle tissue in response to mechanical stress such as resistance exercise or injury. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine manner to activate muscle satellite cells and initiate local repair processes. It is a research peptide studied for its role in muscle regeneration, injury recovery, and exercise-induced adaptation.

Mechanism of Action

Splice variant of IGF-1 produced in response to mechanical loading (exercise). Activates satellite cells in muscle tissue, promoting myoblast proliferation and muscle repair. Acts locally at the site of muscle damage before being converted to systemic IGF-1.

Research Protocols

For research purposes only. Not medical advice.

Research protocols use 100-200mcg per injection, administered intramuscularly into the target muscle immediately post-workout. Very short half-life requires local administration. Cycles of 4-6 weeks.

Research Notes

Clinical Research Status

MGF remains a preclinical research compound with no formal clinical trials conducted in humans for any therapeutic indication. Academic research has focused on understanding its role in exercise-induced muscle repair and satellite cell activation using in vitro and animal models. The synthetic peptide form used in research represents the C-terminal 24-amino acid sequence unique to the MGF splice variant (the E-domain peptide).

Key Published Findings

Research demonstrates that MGF expression peaks 24-72 hours after muscle damage, preceding the systemic IGF-1Ea isoform expression that follows later in the repair process. In vitro studies show the MGF E-domain peptide activates quiescent satellite cells, promoting their proliferation without immediate differentiation, effectively expanding the myogenic progenitor pool. Animal studies indicate local MGF injection can enhance muscle regeneration after injury, with up to 25% greater muscle mass recovery compared to controls.

Safety Profile

No formal human safety data exists for synthetic MGF peptide administration. The short half-life (minutes when unmodified) limits both efficacy and potential for adverse effects from systemic exposure. Theoretical concerns include uncontrolled satellite cell proliferation and potential interference with normal muscle repair signaling cascades. The extremely rapid degradation of unPEGylated MGF in plasma raises questions about whether injected peptide reaches target tissues at meaningful concentrations.

Comparison to Related Compounds

Unlike IGF-1 LR3 which has potent systemic anabolic effects, MGF is designed for local autocrine/paracrine muscle repair signaling with minimal systemic activity. PEG-MGF extends the half-life through PEGylation, converting it from a locally-acting to a more systemically-active peptide. Compared to full-length IGF-1, MGF specifically targets satellite cell activation (proliferation phase) rather than the differentiation and hypertrophy phases driven by IGF-1Ea.

Community Observations

Researchers note that unmodified MGF's extremely short half-life of 5-7 minutes in plasma makes systemic injection largely impractical for achieving meaningful local muscle concentrations. Some protocols suggest intramuscular injection directly into target muscles immediately post-exercise to approximate the natural local expression pattern. The distinction between MGF's satellite cell activating role and IGF-1's downstream hypertrophy signaling represents an important conceptual framework for understanding muscle repair biology.

Half Life

~5-7 minutes

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 12 months.

Reconstituted

Refrigerate 2-8C. Use within 7 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Mechano Growth FactorIGF-1Ec

Frequently Asked Questions

What is MGF?

Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (specifically the IGF-1Ec isoform in humans) that is expressed locally in muscle tissue in response to mechanical stress such as resistance exercise or injury. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine manner to activate muscle satellite cells and initiate local repair processes. It is a research peptide studied for its role in muscle regeneration, injury recovery, and exercise-induced adaptation.

How does MGF work?

Splice variant of IGF-1 produced in response to mechanical loading (exercise). Activates satellite cells in muscle tissue, promoting myoblast proliferation and muscle repair. Acts locally at the site of muscle damage before being converted to systemic IGF-1.

What is the US regulatory status of MGF?

Research chemical (not FDA-approved)

What is the half-life of MGF?

~5-7 minutes

What else is MGF called?

Mechano Growth Factor, IGF-1Ec

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer